A multicenter, randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of MEM 1003 [Memory Pharmaceuticals] in patients with mild to moderate Alzheimer's disease

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of MEM 1003 [Memory Pharmaceuticals] in patients with mild to moderate Alzheimer's disease

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2010

At a glance

  • Drugs MEM 1003 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Memory Pharmaceuticals
  • Most Recent Events

    • 06 Mar 2008 Primary endpoint not reached, according to a Memory Pharmaceuticals media release.
    • 16 Oct 2007 Top-line results reported
    • 16 Oct 2007 Status change from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top